Kenneth A Iczkowski, MD | Medical College of Wisconsin

Kenneth A. Iczkowski, MD

Professor

view physician profile

Locations

Pathology - Froedtert Hospital

Specialties

Pathology - Anatomic

Languages

English

Education

MD - Doctor of Medicine

Biography

Dr. lczkowski is the urologic (GU) pathologist for the Froedtert & the Medical College of Wisconsin. He also covers some general surgical pathology and heart biopsy specimens. He has ongoing research in prostate pathology and teaches residents and students.

Research Interests

My current research revolves around the importance of prostate cancer morphology with respect to outcome and radiologic correlations. This includes studies such as:

Refining the Gleason grading criteria (Journal of Urology, 2016; 196(4):1076-81} and proposing incorporation of the cribriform pattern of cancer into diagnostic prostate pathology (The new realization about cribriform prostate cancer. Advances in Anatomic Pathology 2018; 25:31-37.)

Correlations with molecular expression of important markers PTEN and p27 (PTEN and p27 loss}

Racial disparity in expression of pro-inflammatory markers in prostate cancer

Assisting Dr. Peter LaViolette (radiology) with histologic-radiologic correlation of prostate pathology (Predictive Cytological Topography (PiCT))

Macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer; MIF gene polymorphisms which are associated with susceptibility and severity of prostate cancer. U.S. Patent No. 7,745,121.

Assisting Dr. Marja Nevalainen with prostate tissue procurement for the study of STATS and related molecules

PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.

(Singh CK, Denu RA, Nihal M, Shabbir M, Garvey DR, Huang W, Iczkowski KA, Ahmad N.) Prostate. 2022 Jun;82(9):957-969 PMID: 35333404 PMCID: PMC9090996 SCOPUS ID: 2-s2.0-85127235566 03/26/2022
Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.

(McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, Quarles CC, Prah MA, Schmainda KM, Taouli B, LoCastro E, Mazaheri Y, Shukla-Dave A, Yankeelov TE, Hormuth DA 2nd, Madhuranthakam AJ, Hulsey K, Li K, Huang W, Huang W, Muzi M, Jacobs MA, Solaiyappan M, Hectors S, Antic T, Paner GP, Palangmonthip W, Jacobsohn K, Hohenwalter M, Duvnjak P, Griffin M, See W, Nevalainen MT, Iczkowski KA, LaViolette PS.) J Magn Reson Imaging. 2022 06;55(6):1745-1758 PMID: 34767682 PMCID: PMC9095769 SCOPUS ID: 2-s2.0-85118887092 11/13/2021
Inverse co-expression of EZH2 and acetylated H3K27 in prostatic tissue.

(Puzyrenko A, Kumar SN, Pantazis CG, Iczkowski KA.) Ann Diagn Pathol. 2022 Apr 27;59:151956 PMID: 35509134 SCOPUS ID: 2-s2.0-85129373666 05/06/2022
Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions.

(Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M.) Kidney Int. 2022 04;101(4):766-778 PMID: 35114200 PMCID: PMC8940673 SCOPUS ID: 2-s2.0-85125312317 02/04/2022
Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice.

(Chhabra G, Singh CK, Guzmán-Pérez G, Ndiaye MA, Iczkowski KA, Ahmad N.) J Invest Dermatol. 2022 04;142(4):1145-1157.e7 PMID: 34597611 SCOPUS ID: 2-s2.0-85121721802 10/02/2021
Diffusion Restriction Comparison between Gleason 4 Fused Glands and Cribriform Glands within Patient Using Whole-Mount Prostate Pathology as Ground Truth.

(Duenweg SR, Fang X, Bobholz SA, Lowman AK, Brehler M, Kyereme F, Iczkowski KA, Jacobsohn KM, Banerjee A, LaViolette PS.) Tomography. 2022 03 02;8(2):635-643 PMID: 35314630 PMCID: PMC8938782 SCOPUS ID: 2-s2.0-85125945301 03/23/2022
Small cell carcinoma of the urinary bladder: Distinctive cytological characteristics and Cyto-histologic correlation

(Puzyrenko A, Nomani L, Iczkowski K, Giorgadze T.) Annals of Diagnostic Pathology. August 2022;59 SCOPUS ID: 2-s2.0-85127923115 08/01/2022
Diffusion Restriction Comparison between Gleason 4 Fused Glands and Cribriform Glands within Patient Using Whole-Mount Prostate Pathology as Ground Truth

(Duenweg SR, Fang X, Bobholz SA, Lowman AK, Brehler M, Kyereme F, Iczkowski KA, Jacobsohn KM, Banerjee A, Laviolette PS.) Tomography. April 2022;8(2):635-643 SCOPUS ID: 2-s2.0-85125945301 04/01/2022
Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification.

(Huang W, Randhawa R, Jain P, Iczkowski KA, Hu R, Hubbard S, Eickhoff J, Basu H, Roy R.) JAMA Netw Open. 2021 11 01;4(11):e2132554 PMID: 34730818 PMCID: PMC8567112 SCOPUS ID: 2-s2.0-85118947589 11/04/2021
Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

(Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT.) Cancers (Basel). 2021 Oct 17;13(20) PMID: 34680353 PMCID: PMC8533841 10/24/2021
Peripheral antinociceptive effects of a bifunctional μ and δ opioid receptor ligand in rat model of inflammatory bladder pain.

(Terashvili M, Talluri B, Palangmonthip W, Iczkowski KA, Sanvanson P, Medda BK, Banerjee B, Cunningham CW, Sengupta JN.) Neuropharmacology. 2021 09 15;196:108701 PMID: 34256047 PMCID: PMC8435000 SCOPUS ID: 2-s2.0-85110016880 07/14/2021
Second-generation jak2 inhibitors for advanced prostate cancer: Are we ready for clinical development?

(Beinhoff P, Sabharwal L, Udhane V, Maranto C, Laviolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT.) Cancers. October-2 2021;13(20) SCOPUS ID: 2-s2.0-85117018634 10/01/2021